Hematopoietic growth factors in neonatal medicine:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2004
|
| Schriftenreihe: | Clinics in perinatology
31,1 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIV, 198 S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV019340666 | ||
| 003 | DE-604 | ||
| 005 | 20160223 | ||
| 007 | t | ||
| 008 | 040720s2004 d||| |||| 00||| eng d | ||
| 035 | |a (OCoLC)55850460 | ||
| 035 | |a (DE-599)BVBBV019340666 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 |a DE-578 |a DE-20 | ||
| 050 | 0 | |a RJ269.5 | |
| 082 | 0 | |a 618.9215 |2 22 | |
| 084 | |a YQ 2500 |0 (DE-625)154055:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Hematopoietic growth factors in neonatal medicine |c guest ed.: Robert D. Christensen |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2004 | |
| 300 | |a XIV, 198 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Clinics in perinatology |v 31,1 | |
| 650 | 7 | |a Bloedvorming |2 gtt | |
| 650 | 7 | |a Hepatocyte groeifactor |2 gtt | |
| 650 | 7 | |a Neonatologie |2 gtt | |
| 650 | 4 | |a Cross Infection |x prevention & control |x Infant, Newborn | |
| 650 | 4 | |a Cytokines |x physiology | |
| 650 | 4 | |a Enterocolitis, Necrotizing |x Infant, Newborn | |
| 650 | 4 | |a Hematologic Diseases |x Infant, Newborn | |
| 650 | 4 | |a Hematopoietic Cell Growth Factors |x therapeutic use |x Infant, Newborn | |
| 650 | 4 | |a Hematopoietic growth factors |x Terapeutic use | |
| 650 | 4 | |a Neonatal hematology | |
| 650 | 4 | |a Nervous System Diseases |x Infant, Newborn | |
| 650 | 4 | |a Newborn infants |x Abnormalities |x Treatment | |
| 650 | 4 | |a Sepsis |x Infant, Newborn | |
| 650 | 0 | 7 | |a Neugeborenes |0 (DE-588)4041781-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Hämatopoese |0 (DE-588)4113823-5 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Neugeborenes |0 (DE-588)4041781-5 |D s |
| 689 | 0 | 1 | |a Hämatopoese |0 (DE-588)4113823-5 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Christensen, Robert D. |e Sonstige |0 (DE-588)1076853773 |4 oth | |
| 830 | 0 | |a Clinics in perinatology |v 31,1 |w (DE-604)BV000003382 |9 31,1 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=012805208&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-012805208 | ||
Datensatz im Suchindex
| _version_ | 1804132764581101568 |
|---|---|
| adam_text | MLMAIUI OII.IK i.KUVMII I-A( IDI^I I.U MAI. MIDKI.M
CONTENTS
Preface xiii
Robert D. Christensen
Evaluation and Treatment of Severe and Prolonged
Thrombocytopenia in Neonates 1
Martha C. Sola
Thrombocytopenia is one of the most common hematologic prob¬
lems in the neonatal intensive care unit (NICU). Despite its preva¬
lence, several basic pathophysiologic questions remain unanswered.
For instance, there is a lack of evidence-based guidelines for treat¬
ment, and the kinetic mechanisms (decreased platelet production,
increased platelet consumption, or sequestration) responsible for
most varieties of neonatal thrombocytopenia are not well defined.
Moreover, a clear correlation between degree of thrombocytopenia
and the resulting bleeding risk has not been demonstrated, and no
transfusion-trigger studies have been conducted in neonates. As a
consequence of these deficiencies in knowledge, there is great vari¬
ability in platelet transfusion practices among NICUs. This article
presents an overview of the evaluation of a neonate with severe
thrombocytopenia and a review of current and projected thera¬
peutic options.
Platelet Function in Term and Preterm Neonates 15
Matthew A. Saxonhouse and Martha C. Sola
Platelet dysfunction likely contributes to the pathophysiology of
catastrophic hemorrhages in preterm neonates. In vitro studies
have demonstrated that platelets of both term and preterm
neonates are hyporesponsive to a variety of agonists. In contrast,
template bleeding times of term neonates are shorter than those
from adults. Very little is known about this and other tests of pri¬
mary hemostasis in premature and sick neonates in the neonatal
VOLUME 31 • NUMBER 1 • MARCH 2004 v
intensive care unit (NICU). This article covers the current knowl¬
edge of platelet function in preterm and term neonates and reviews
how new agents (such as recombinant thrombopoietin and recom-
binant factor Vila) may enhance neonatal platelet function.
Congenital Neutropenia 29
Robert D. Christensen and Darlene A. Calhoun
The term congenital neutropenia signifies neutropenia that is
present at birth. It includes a wide variety of disorders, some tran¬
sient and others life long. Some varieties of congenital neutrope¬
nia are mild, with blood neutrophil concentrations below normal
but not low enough to constitute a significant host defense defi¬
ciency. Other varieties of congenital neutropenia are characterized
by low blood neutrophil concentrations and a predisposition to
repeated infections.
Neonatal Neutrophils: The Good, The Bad, and The Ugly 39
Joyce M. Koenig and Mervin C. Yoder
Neonates are at considerable risk for bacterial and fungal infec¬
tions, due in great part to a variety of age-related impairments in
neutrophil function. In addition, evidence suggests that the ten¬
dency of the most immature neonates to develop chronic inflam¬
matory disorders is also related to neutrophil dysfunction. This
article provides an overview of specific functional deficiencies of
neutrophils that have been reported in neonates.
The Role of Molecular Genetics in the Pathogenesis and
Diagnosis of Neonatal Sepsis 53
Antonio Del Vecchio, Nicola Laforgia, Mario Capasso,
Achille Iolascon, and Giuseppe Latini
Polymorphisms within genes encoding endogenous mediators of
inflammation are good candidates for the individual differences
in systemic inflammatory responses of neonates to infection. In
a similar manner, polymorphisms in the genes encoding drug-
metabolizing enzymes, drug transporters, and drug receptors can
influence a neonate s risk of an adverse drug reaction or can alter
the efficacy of drug treatment. Additionally, molecular tools are
proving valuable in the diagnosis of neonatal infection. This article
gives an overview of the genetic susceptibility to sepsis, discusses
the use of molecular genetics in diagnostic tests for infection, and
reviews the potential for more effective and specific therapies for
sepsis based on genetic variability.
vi CONTENTS
Immunoenhancement to Prevent Nosocomial Coagulase-
Negative Staphylococcal Sepsis in Very Low-Birth-
Weight Infants 69
Lori A. Devlin and Herbert A. Lassiter
Extremely low-birth-weight infants are susceptible to invasion by
coagulase-negative staphylococci (CONS). This article reviews the
epidemiology, immunology, and microbiology of CONS and
describes recent clinical trials of immunoenhancing agents such
as intravenous immunoglobulin, granulocyte colony-stimulating
factor, granulocyte macrophage colony-stimulating factor, and
mouse humanized chimeric anti-lipoteichoic acid antibody.
Potential avenues of research to reduce the incidence of nosocomial
CONS sepsis in premature neonates are presented.
Long-Acting Erythropoietin: Clinical Studies and Potential
Uses in Neonates 77
Robin K. Ohls and Aihua Dai
Aranesp (darbepoietin alfa) is a biologically modified form of re-
combinant human erythropoietin (rHuEpo). Two additional
carbohydrate-binding sites give Aranesp a half-life about three
times that of rHuEpo. Extensive studies in adults and early studies
in children indicate that Aranesp can be administered far less
frequently than rHuEpo with an equivalent erythropoietic effect.
This article reviews these studies and reports on the in vitro effects
of Aranesp on human fetal and neonatal erythroid progenitors.
Nuclear Mechanisms of Hypoxic Cerebral Injury in
the Newborn 91
Maria Delivoria-Papadopoulos and Om Prakash Mishra
In early studies, we demonstrated that cerebral tissue hypoxia
leads to N-methyl-D-aspartate receptor modification and results in
increased intracellular Ca2+. Our subsequent studies have demon¬
strated an alteration in nuclear Ca2+ influx mechanisms and an
increase in the nuclear Ca2+ influx after hypoxia. The hypoxia-
induced nuclear Ca2+ influx increase correlated in a curvilinear
function with the increase in the degree of cerebral tissue hypoxia.
The activity of nuclear membrane high-affinity Ca2+-ATPase also
increased with the increase in cerebral hypoxia. The expression of
the proapototic protein Bax increased as an inverse function with
cerebral tissue ATP and phosphocreatine concentrations. However,
the expression of the antiapoptotic protein Bcl-2 did not increase
after hypoxia. Cerebral tissue hypoxia also led to the activation of
caspases 3, 8, and 9. Furthermore, our studies demonstrated that
the fragmentation of neuronal genomic DNA increased with
increase in degree of cerebral tissue hypoxia. Studies presented in
this article elucidate nuclear Ca2+ influx and nuclear Ca2+-mediated
CONTENTS vii
mechanisms, including signal transduction, apoptotic gene tran¬
scription, caspase activation, and nuclear DNA fragmentation, that
result in hypoxic neuronal injury in the newborn brain.
Biomarkers of Hypoxic Brain Injury in the Neonate 107
Giuseppe Buonocore and Serafina Perrone
The specific pathologic processes preceding the onset of irre¬
versible cerebral injury seem to be a combination of several complex
mechanisms due to the severity and duration of the insult to the
biochemical modifications in the brain. An early diagnosis of
the newborn at high risk for brain damage is relevant for preven¬
tive programs. Neuroprotective strategies will benefit from the
detection of biochemical markers with high reliability and pre¬
dictability for brain injury.
The Role of Complement in Neonatal Hypoxic-Ischemic
Cerebral Injury 117
Herbert A. Lassiter
Complement activation participates in tissue injury after tempo¬
rary loss of blood flow (ischemia-reperfusion injury). Recently
reported evidence indicates that complement activation is a patho¬
logic mechanism of injury in the post-hypoxic-ischemic neonatal
brain. Therefore, recently developed complement inhibitors may
find a role in the amelioration of neonatal hypoxic-ischemic cere¬
bral injury. Further research is needed to better define the role of
complement in human neonatal cerebral injury and to determine
the neuroprotective effect and safety of pharmacologic agents
designed to inhibit complement.
Recombinant Erythropoietin as a Neuroprotective Treatment:
In Vitro and In Vivo Models 129
Sandra Juul
The biologic effects of erythropoietin in the central and peripheral
nervous system involve the activation of its specific cell surface
receptor and corresponding signal transduction pathways. This
article reviews the neuroprotective effects of erythropoietin in
brain, emphasizing the progress made using in vitro and in vivo
research models.
Role of Cytokines in Human Intestinal Villous Development 143
Akhil Maheshwari
Villous development of the intestine is beginning to be understood
in terms of the underlying molecular mechanisms. There is increas¬
ing information on the role of cytokines as extrinsic regulators in
this process. This article summarizes information available on
various cytokines that have been studied in this context.
viii CONTENTS
Necrotizing Enterocolitis: Preventative Strategies 157
Kristina M. Reber and Craig A. Nankervis
Necrotizing enterocolitis (NEC) remains a major cause of morbidity
and mortality in premature infants. Although the pathogenesis of
NEC is unclear, prevention strategies have been developed based
on clinical observations and epidemiologic and experimental data.
Most current strategies have centered on feeding practices (eg, insti¬
tution of feeds, advancement of feeds, composition of feeds, and
standardization of feeding practices). Emerging strategies include
amino acid supplementation, the use of platelet-activating factor
(PAF) antagonists or PAF-acetylhydrolase administration, polyun-
saturated fatty acid administration, epidermal growth factor
administration, and the use of pre- and probiotics.
Hematopoietic Growth Factors in Neonatal Medicine: The Use
of Enterally Administered Hematopoietic Growth Factors in
the Neonatal Intensive Care Unit 169
Darlene A. Calhoun and Robert D. Christensen
The practice of complete bowel rest in prematurely delivered
neonates and those who have undergone surgery for congenital
anomalies of the gastrointestinal (GI) tract is common in neonatal
intensive care units (NICU). However, increased recognition of the
critical role of growth factors in GI development suggests that this
practice might be modified to include the administration of syn¬
thetic amniotic fluid-like solutions designed to bridge the neonate
between their intra-uterine environment and that of the NICU.
This article reviews advances in administering synthetic amniotic
fluid-like solutions in the NICU.
Epidermal Growth Factor and Necrotizing Enterocolitis 183
Bohuslav Dvorak
As the number of extremely low-birth-weight infants increases,
necrotizing enterocolitis remains a critical eminent problem. Sup¬
plementation of enteral feeds with biologically active substances
normally present in breast milk, such as epidermal growth factor,
seems to be a logical and safe way to reduce the incidence of intes¬
tinal inflammation and necrotizing enterocolitis. Continuing basic
research and clinical studies are essential before epidermal growth
factor can be introduced as an efficient therapeutic approach in the
treatment of neonatal necrotizing enterocolitis.
Index 193
CONTENTS »x
|
| any_adam_object | 1 |
| author_GND | (DE-588)1076853773 |
| building | Verbundindex |
| bvnumber | BV019340666 |
| callnumber-first | R - Medicine |
| callnumber-label | RJ269 |
| callnumber-raw | RJ269.5 |
| callnumber-search | RJ269.5 |
| callnumber-sort | RJ 3269.5 |
| callnumber-subject | RJ - Pediatrics |
| classification_rvk | YQ 2500 |
| ctrlnum | (OCoLC)55850460 (DE-599)BVBBV019340666 |
| dewey-full | 618.9215 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 618 - Gynecology, obstetrics, pediatrics, geriatrics |
| dewey-raw | 618.9215 |
| dewey-search | 618.9215 |
| dewey-sort | 3618.9215 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02206nam a2200541 cb4500</leader><controlfield tag="001">BV019340666</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160223 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">040720s2004 d||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)55850460</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV019340666</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-578</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RJ269.5</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">618.9215</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YQ 2500</subfield><subfield code="0">(DE-625)154055:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hematopoietic growth factors in neonatal medicine</subfield><subfield code="c">guest ed.: Robert D. Christensen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 198 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Clinics in perinatology</subfield><subfield code="v">31,1</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bloedvorming</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatocyte groeifactor</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neonatologie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cross Infection</subfield><subfield code="x">prevention & control</subfield><subfield code="x">Infant, Newborn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cytokines</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enterocolitis, Necrotizing</subfield><subfield code="x">Infant, Newborn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematologic Diseases</subfield><subfield code="x">Infant, Newborn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematopoietic Cell Growth Factors</subfield><subfield code="x">therapeutic use</subfield><subfield code="x">Infant, Newborn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematopoietic growth factors</subfield><subfield code="x">Terapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neonatal hematology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nervous System Diseases</subfield><subfield code="x">Infant, Newborn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Newborn infants</subfield><subfield code="x">Abnormalities</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sepsis</subfield><subfield code="x">Infant, Newborn</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Neugeborenes</subfield><subfield code="0">(DE-588)4041781-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hämatopoese</subfield><subfield code="0">(DE-588)4113823-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Neugeborenes</subfield><subfield code="0">(DE-588)4041781-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Hämatopoese</subfield><subfield code="0">(DE-588)4113823-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christensen, Robert D.</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)1076853773</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Clinics in perinatology</subfield><subfield code="v">31,1</subfield><subfield code="w">(DE-604)BV000003382</subfield><subfield code="9">31,1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=012805208&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-012805208</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV019340666 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T19:58:00Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-012805208 |
| oclc_num | 55850460 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-578 DE-20 |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-578 DE-20 |
| physical | XIV, 198 S. graph. Darst. |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Saunders |
| record_format | marc |
| series | Clinics in perinatology |
| series2 | Clinics in perinatology |
| spelling | Hematopoietic growth factors in neonatal medicine guest ed.: Robert D. Christensen Philadelphia [u.a.] Saunders 2004 XIV, 198 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Clinics in perinatology 31,1 Bloedvorming gtt Hepatocyte groeifactor gtt Neonatologie gtt Cross Infection prevention & control Infant, Newborn Cytokines physiology Enterocolitis, Necrotizing Infant, Newborn Hematologic Diseases Infant, Newborn Hematopoietic Cell Growth Factors therapeutic use Infant, Newborn Hematopoietic growth factors Terapeutic use Neonatal hematology Nervous System Diseases Infant, Newborn Newborn infants Abnormalities Treatment Sepsis Infant, Newborn Neugeborenes (DE-588)4041781-5 gnd rswk-swf Hämatopoese (DE-588)4113823-5 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Neugeborenes (DE-588)4041781-5 s Hämatopoese (DE-588)4113823-5 s b DE-604 Christensen, Robert D. Sonstige (DE-588)1076853773 oth Clinics in perinatology 31,1 (DE-604)BV000003382 31,1 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=012805208&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Hematopoietic growth factors in neonatal medicine Clinics in perinatology Bloedvorming gtt Hepatocyte groeifactor gtt Neonatologie gtt Cross Infection prevention & control Infant, Newborn Cytokines physiology Enterocolitis, Necrotizing Infant, Newborn Hematologic Diseases Infant, Newborn Hematopoietic Cell Growth Factors therapeutic use Infant, Newborn Hematopoietic growth factors Terapeutic use Neonatal hematology Nervous System Diseases Infant, Newborn Newborn infants Abnormalities Treatment Sepsis Infant, Newborn Neugeborenes (DE-588)4041781-5 gnd Hämatopoese (DE-588)4113823-5 gnd |
| subject_GND | (DE-588)4041781-5 (DE-588)4113823-5 (DE-588)4143413-4 |
| title | Hematopoietic growth factors in neonatal medicine |
| title_auth | Hematopoietic growth factors in neonatal medicine |
| title_exact_search | Hematopoietic growth factors in neonatal medicine |
| title_full | Hematopoietic growth factors in neonatal medicine guest ed.: Robert D. Christensen |
| title_fullStr | Hematopoietic growth factors in neonatal medicine guest ed.: Robert D. Christensen |
| title_full_unstemmed | Hematopoietic growth factors in neonatal medicine guest ed.: Robert D. Christensen |
| title_short | Hematopoietic growth factors in neonatal medicine |
| title_sort | hematopoietic growth factors in neonatal medicine |
| topic | Bloedvorming gtt Hepatocyte groeifactor gtt Neonatologie gtt Cross Infection prevention & control Infant, Newborn Cytokines physiology Enterocolitis, Necrotizing Infant, Newborn Hematologic Diseases Infant, Newborn Hematopoietic Cell Growth Factors therapeutic use Infant, Newborn Hematopoietic growth factors Terapeutic use Neonatal hematology Nervous System Diseases Infant, Newborn Newborn infants Abnormalities Treatment Sepsis Infant, Newborn Neugeborenes (DE-588)4041781-5 gnd Hämatopoese (DE-588)4113823-5 gnd |
| topic_facet | Bloedvorming Hepatocyte groeifactor Neonatologie Cross Infection prevention & control Infant, Newborn Cytokines physiology Enterocolitis, Necrotizing Infant, Newborn Hematologic Diseases Infant, Newborn Hematopoietic Cell Growth Factors therapeutic use Infant, Newborn Hematopoietic growth factors Terapeutic use Neonatal hematology Nervous System Diseases Infant, Newborn Newborn infants Abnormalities Treatment Sepsis Infant, Newborn Neugeborenes Hämatopoese Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=012805208&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003382 |
| work_keys_str_mv | AT christensenrobertd hematopoieticgrowthfactorsinneonatalmedicine |